Goran Babic Selected Research

GP2015

1/2019	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
1/2018	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Goran Babic Research Topics

Disease

4	Rheumatoid Arthritis 01/2019 - 09/2008
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2019
1	Rheumatic Diseases (Rheumatism) 01/2018
1	Disease Progression 09/2008
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2008

Drug/Important Bio-Agent (IBA)

2	Etanercept (Enbrel)FDA Link 01/2019 - 01/2018
2	GP2015IBA 01/2019 - 01/2018
2	Antirheumatic Agents (DMARD)IBA 01/2019 - 01/2018
2	Biosimilar PharmaceuticalsIBA 01/2019 - 01/2018
1	GP1111IBA 01/2019
1	Infliximab (Remicade)FDA Link 01/2019
1	Biological ProductsIBA 01/2018
1	Rituximab (Mabthera)FDA Link 09/2008

Therapy/Procedure

1	Therapeutics 09/2008